KR20250026152A - 근위축성 측색경화증의 치료제 또는 예방제 - Google Patents

근위축성 측색경화증의 치료제 또는 예방제 Download PDF

Info

Publication number
KR20250026152A
KR20250026152A KR1020247034823A KR20247034823A KR20250026152A KR 20250026152 A KR20250026152 A KR 20250026152A KR 1020247034823 A KR1020247034823 A KR 1020247034823A KR 20247034823 A KR20247034823 A KR 20247034823A KR 20250026152 A KR20250026152 A KR 20250026152A
Authority
KR
South Korea
Prior art keywords
group
mmol
atom
tetrahydroquinolin
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247034823A
Other languages
English (en)
Korean (ko)
Inventor
미즈에 오가와
타케히로 타카하시
코즈에 타카가키
히로유키 메구로
켄 누네츠 아사바
마사시 야마모토
마리나 노가미
리이치로 츠지
나오야 우케가와
Original Assignee
도레이 카부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 도레이 카부시키가이샤 filed Critical 도레이 카부시키가이샤
Publication of KR20250026152A publication Critical patent/KR20250026152A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247034823A 2022-06-24 2023-06-23 근위축성 측색경화증의 치료제 또는 예방제 Pending KR20250026152A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022101476 2022-06-24
JPJP-P-2022-101476 2022-06-24
PCT/JP2023/023264 WO2023249106A1 (ja) 2022-06-24 2023-06-23 筋萎縮性側索硬化症の治療剤又は予防剤

Publications (1)

Publication Number Publication Date
KR20250026152A true KR20250026152A (ko) 2025-02-25

Family

ID=89380133

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247034823A Pending KR20250026152A (ko) 2022-06-24 2023-06-23 근위축성 측색경화증의 치료제 또는 예방제

Country Status (8)

Country Link
US (1) US20260083723A1 (https=)
EP (1) EP4545079A1 (https=)
JP (1) JPWO2023249106A1 (https=)
KR (1) KR20250026152A (https=)
CN (1) CN119403554A (https=)
AU (1) AU2023286251A1 (https=)
CA (1) CA3256001A1 (https=)
WO (1) WO2023249106A1 (https=)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5651456A (en) 1979-09-13 1981-05-09 Wellcome Found 22phenyltetraline derivative
JPH05125052A (ja) 1991-04-16 1993-05-21 Kyorin Pharmaceut Co Ltd 新規環状アミノフエニル酢酸誘導体、その製造法及びそれらを有効成分とする免疫応答の修飾剤
KR100236910B1 (ko) 1992-12-14 2000-04-01 김영환 고집적 반도체 기억소자의 메모리셀어레이 제조방법
WO2005063735A1 (de) 2003-12-20 2005-07-14 Merck Patent Gmbh 2- (hetero) -arylsubstituierte tetrahydrochinolinderivate
WO2007054138A1 (de) 2005-06-13 2007-05-18 Merck Patent Gmbh Substituierte tetrahydrochinoline
WO2013035712A1 (ja) 2011-09-05 2013-03-14 田辺三菱製薬株式会社 筋萎縮性側索硬化症の治療又は病勢進展抑制のための薬剤
CN110372614A (zh) 2019-07-03 2019-10-25 山东师范大学 一种四氢喹喔啉类化合物及制备方法与应用
CN110464727A (zh) 2019-09-06 2019-11-19 山东师范大学 3,4-二氢-2h-苯并-[1,4]恶嗪类药物或其盐在制备抑制铁死亡药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10236910A1 (de) 2002-08-12 2004-03-11 Grünenthal GmbH Substituierte 1,2,3,4-Tetrahydrochinolinderivate
EP2733138B1 (en) * 2011-07-15 2016-09-28 Hamari Chemicals, Ltd. Method for producing optically active tetrahydroquinoline
WO2019106434A1 (en) * 2017-12-01 2019-06-06 Collaborative Medicinal Development Pty. Ltd. Heterobicyclic aromatic derivatives for the treatment of ferroptosis-related disorders
CN113631535B (zh) * 2019-03-11 2024-04-12 协同医药发展有限公司 治疗铁死亡相关紊乱的杂芳基和双杂环芳基衍生物
IL303307A (en) * 2020-12-25 2023-07-01 Toray Industries Tetrahydroquinoline derivative and its medical use

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5651456A (en) 1979-09-13 1981-05-09 Wellcome Found 22phenyltetraline derivative
JPH05125052A (ja) 1991-04-16 1993-05-21 Kyorin Pharmaceut Co Ltd 新規環状アミノフエニル酢酸誘導体、その製造法及びそれらを有効成分とする免疫応答の修飾剤
KR100236910B1 (ko) 1992-12-14 2000-04-01 김영환 고집적 반도체 기억소자의 메모리셀어레이 제조방법
WO2005063735A1 (de) 2003-12-20 2005-07-14 Merck Patent Gmbh 2- (hetero) -arylsubstituierte tetrahydrochinolinderivate
WO2007054138A1 (de) 2005-06-13 2007-05-18 Merck Patent Gmbh Substituierte tetrahydrochinoline
WO2013035712A1 (ja) 2011-09-05 2013-03-14 田辺三菱製薬株式会社 筋萎縮性側索硬化症の治療又は病勢進展抑制のための薬剤
CN110372614A (zh) 2019-07-03 2019-10-25 山东师范大学 一种四氢喹喔啉类化合物及制备方法与应用
CN110464727A (zh) 2019-09-06 2019-11-19 山东师范大学 3,4-二氢-2h-苯并-[1,4]恶嗪类药物或其盐在制备抑制铁死亡药物中的应用

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Dixon 등, Cell, 2012, 제149권, p. 1060-1072
Hong-Xu Lei 등, Journal of Molecular Structure, 2021, 제1228권, 129485
Jennifer Yinus Cao 등, Cellular and Molecular Life Science, 2016, 제73권, p2195-2209
Jeong 등, Journal Of Neuroscience, 2009, 29권 3호, p. 610-619
Lars 등, Journal of Medicinal Chemistry, 2018, 전61권, p. 10126-10140
Liddell 등, bioRxiv, 2022, 전인쇄
Yu-Zhen Li 등, Frontiers in Chemistry, 2019, 제7권, 850

Also Published As

Publication number Publication date
WO2023249106A1 (ja) 2023-12-28
EP4545079A1 (en) 2025-04-30
AU2023286251A1 (en) 2024-12-05
US20260083723A1 (en) 2026-03-26
CN119403554A (zh) 2025-02-07
JPWO2023249106A1 (https=) 2023-12-28
CA3256001A1 (en) 2025-03-18

Similar Documents

Publication Publication Date Title
TWI814882B (zh) 新穎雜環化合物
KR102947968B1 (ko) 테트라히드로퀴놀린 유도체 및 그 의약 용도
TWI444369B (zh) Canine Urethane Production Inhibitors
JP2019182869A (ja) 疾患治療用のグルコシルセラミドシンターゼ阻害剤
CN111936503A (zh) 噁嗪单酰甘油脂肪酶(magl)抑制剂
WO2001096308A1 (en) 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
CN103012259A (zh) 1,4-二取代的3-氰基-吡啶酮衍生物及其作为mglur2受体正性变构调节剂的用途
CN101094848A (zh) 有机化合物
WO2020103817A1 (zh) TGF-βR1抑制剂及其应用
TW201706275A (zh) 具有ｈｉｖ複製抑制作用之含氮３環性衍生物
KR102537615B1 (ko) 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
TW201643140A (zh) ６員雜環衍生物及含有彼等之醫藥組合物
WO2020192650A1 (zh) 酰胺类化合物制备方法及其在医药领域的应用
CN102046618A (zh) 羟基喹喔啉甲酰胺衍生物
CN111356695A (zh) 新的三环化合物
CN112513041B (zh) 三环化合物
KR20250026152A (ko) 근위축성 측색경화증의 치료제 또는 예방제
TWI917519B (zh) 四氫喹啉衍生物及其醫藥用途
RU2850795C1 (ru) Производное тетрагидрохинолина и его медицинское применение
HK40096343A (zh) 四氢喹啉衍生物及其医药用途
WO2023249105A1 (ja) 薬剤性心筋障害の治療剤又は予防剤
TW201934558A (zh) 苯并雜芳基類衍生物、其製備方法及其在醫藥上的應用
WO2023249107A1 (ja) 末梢神経障害の治療剤又は予防剤
CN114075141A (zh) 阿片受体“偏向性”配体、其制备方法及其在医药上的应用
CN117777132A (zh) α-N-芳基氨基酰胺及其制备方法和药用用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20241018

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application